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Appropriate Management of Catheter Obstruction
By: Jessica Mercer, PharmD
PGY1 Pharmacy Resident
Central venous lines (CVLs) are
catheters placed into a large vein
with the distal tip extending to a
large vein near the heart. They
can be used to administer medication, obtain blood for laboratory sampling, or to directly
measure certain hemodynamic
parameters. An advantage of
CVLs is that they can have multiple ports, which many medications can be administered
through simultaneously. There
are also medications that are too
caustic to be administered
through peripheral veins and
must be administered through a
CVL. There are complications
associated with CVLs, including
complications during line placement, increased rates of infection, and obstruction of the
catheter.
Catheter obstruction may be due
to a multitude of factors. Common causes include mechanical
obstruction from kinks or torquing, venous obstruction, occlusion of the injection cap, deposits from medications, or blood
clots. The best recommendation
is to take steps to prevent occlusion of CVLs. Catheters should

be maintained and flushed according to the IV Flush order set forth
by the physician*. All heparin
flushes should be scheduled and
documented on the medication
administration record (MAR).
Even with proper maintenance of
CVLs, there is still the potential
for occlusion to occur and the occlusion may be so severe that it
can only be resolved by removing
the catheter. One option is to insert a new line; however, insertion
of CVLs may be associated with
other complications. To decrease
the need to reinsert a new CVL,
there are options for assessing and
managing occluded CVLs.
Occlusion should first be verified
using the flowsheet detailed in
policy C-75 (Figure 1). Other
causes of obstruction besides a
blood clot, fibrin sheath, or medication deposit should be evaluated
and ruled out before proceeding.
The patient should be repositioned or the Valsalva maneuver should be performed to see if
there is a mechanical obstruction
to the catheter. To further evaluate
for mechanical obstruction, the
dressing can be removed to better

* http://www.musc.edu/cce/ORDFRMS/pdf/adultIVflush.PDF
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assess the catheter. The patients should also be assessed for venous obstruction and, if found, the physician
should be notified immediately. If removal of the injection cap still does not produce blood, then the possible
cause of the obstruction should be evaluated. Collaboration with a licensed independent practitioner and a
clinical pharmacist can assist in determining the possible occlusion.
Once the probable cause of the obstruction is determined, a specific pharmacological agent can be administered to clear the occlusion; however, a physician’s order is necessary. Only staff that have documented competency with clearing occluded catheters may perform this procedure (Tables 1 and 2).
Figure 1. Venous Access Device Occlusion Verification Flowsheet
No

Can you aspirate blood from
the catheter?

Does occlusion resolve with the following?
− Patient changes position
− Move arms
− Deep breath
− Valsalva maneuver
− Knee chest position
− Trendelenburg position

Yes

No
Proceed

Are any of the following noted?
− Mechanical obstruction
− Kinks or torquing
− Impinging sutures
− Dislodged needle

Yes
Notify
physician

No
Yes

Does patient have signs and symptoms of venous obstruction?
No
Is blood obtained with removal of the injection cap?

Yes

No
In collaboration with a licensed practitioner and clinical pharmacist, determine the possible cause of obstruction
and proceed based on physician order

A physician’s order is required to clear occluded catheters with any pharmacologic agent.
**Only staff who have documented competency are permitted to clear occluded catheters.**

Suspected acidic
mineral deposit:
▪ 0.1N HCL

Suspected lipid
deposit:
▪ 70% ethyl alcohol

Suspected alkaline
mineral deposit:
▪ 8.4% NaHCO3,
1 mEq/mL

Adapted from Policy C-75, Appendix B1: Venous Access Device Occlusion Verification Flowsheet

Suspected fibrin
sheath or blood clot:
▪ alteplase (Activase®;
Cathflo® Activase®)
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Table 1. Management of a Totally Occluded Catheter
** To be performed only by staff that have documented competency **
Definition – absence of blood flow when aspirating or flushing catheter port(s)
1. Equipment needed
− Pair of gloves
− One three-way stopcock
− One 30-mL vial 0.9% sodium chloride
− Two 10-mL syringes
− One injection cap
− Alcohol prep pads
− Pharmacologic agent ordered to restore patency (volume of agent equal to the internal volume of the catheter) for the
following suspected causes:
Fibrin sheath or blood clot: alteplase (Activase®, Cathflo® Activase®) 2 mg/2 mL in a 3-mL syringe
Acidic mineral deposits (eg, Ca2+, PO4, mineral salts, ampicillin, amikacin, vancomycin): 0.1 N HCL in a 3-mL syringe
Alkaline mineral deposits (eg, phenytoin): sodium bicarbonate 1 mEq/mL, 8.4% in a 3-mL syringe
Lipid deposits: 70% ethyl alcohol in a 3-mL syringe
2. Procedure
− Verify occlusion (Figure 1)
− Clamp occluded catheter lumen
− Using aseptic technique, remove catheter injection cap and attach three-way stopcock directly to the occluded
catheter lumen.
− Withdraw 1 to 2 mL of 0.9% sodium chloride into a 10-mL syringe, label, and attach to the most distal port on the stopcock.
− Withdraw 10 mL of 0.9% sodium chloride into the second 10-mL syringe, label, and set aside for future flushing of port.
− Attach syringe containing the pharmacologic agent to the most proximal port on the stopcock.
− Turn stopcock off to the syringe with the pharmacologic agent and open the syringe with 1 to 2 mL of 0.9% sodium chloride.
− Unclamp occluded catheter lumen.
− Gently pull plunger of the 10-mL syringe back to the 10-mL mark and allow any remaining fluid in the catheter to be
cleared. Once this is complete, turn stopcock off to the 10-mL syringe and on to the syringe containing the pharmacologic
agent. This process creates negative pressure inside the catheter. Opening the stopcock to the syringe containing the pharmacologic agent allows the medication to be gently pulled into the catheter. If medication does not flow in, gentle pressure may
be applied to the syringe to instill the pharmacologic agent.
▪ In pediatrics patients:
− Patients 10 - 30 kg, the volume of the pharmacologic agent should be 110% of the internal lumen volume of the
catheter, not to exceed 2 mg/2 mL for alteplase.
− Patients < 10 kg, the amount of pharmacologic agent should equal the internal volume of the catheter. Do not force the
pharmacologic agent into the catheter.
− Allow the pharmacologic agent to dwell undisturbed for 1 hour
− After 1 hour, turn stopcock off to the syringe of the pharmacologic agent and open to 10-mL syringe and attempt to aspirate.
If blood return is noted, aspirate 5 mL of blood, discard, attach second syringe containing 10 mL of 0.9% sodium chloride
and flush.
▪ In neonates: aspirate 0.5 mL, discard, and flush with 1 mL 0.9% sodium chloride
▪ In pediatric patients: aspirate 1 mL of blood, discard, and flush with 3 mL 0.9% sodium chloride
− If catheter lumen remains occluded, repeat above procedure.
− Notify the medical team if catheter remains occluded after 2 attempts.
− Once catheter patency has been restored, clamp the catheter, remove the stopcock system, and aseptically attach new injection cap to the catheter. Lastly, the catheter should be unclamped. If the catheter is not in use, heparinize catheter according
to institutional policies and procedures.
− Patients receiving alteplase should remain in the patient care setting for 2 to 4 hours; however, they do not have to be confined to bed. Instruct patient/caregiver to report any signs of allergic reaction, bleeding, fever, or shortness of breath. The
stopcock system is the recommended standard. If the patient needs to be off of the patient care unit, or is likely to tamper
with the system, the syringes can be removed and the aseptically stopcock capped.
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Table 2. Management of a Partially Occluded Catheter
** To be performed only by staff that have documented competency **
Definition - Decreased blood flow when aspirating or flushing catheter port(s)
or the catheter flushes but will not aspirate blood.
1. Equipment needed
− Pair of gloves
− One 30-mL vial 0.9% sodium chloride
− Two 10-mL syringes
− Three injection caps
− Alcohol prep pads
− Pharmacologic agent ordered to restore patency (volume of agent equal to the internal volume of the catheter) for the
following suspected causes:
Fibrin sheath or blood clot: alteplase (Activase®, Cathflo® Activase®) 2 mg/2 mL in a 3-mL syringe
Acidic mineral deposits (eg, Ca2+, PO4, mineral salts, ampicillin, amikacin, vancomycin): 0.1 N HCl in a 3-mL syringe
Alkaline mineral deposits (eg, phenytoin): sodium bicarbonate 1 mEq/mL, 8.4% in a 3-mL syringe
Lipid deposits: 70% ethyl alcohol in a 3-mL syringe
2. Procedure
− Verify occlusion (Figure 1)
− Clamp partially occluded catheter lumen.
− Using aseptic technique, remove catheter injection cap and attach 3-mL syringe containing the pharmacologic agent to the
external hub of the catheter.
− Unclamp the catheter, and slowly instill the pharmacologic agent to fill the lumen of the catheter.
− Reclamp the catheter, remove the syringe, and aseptically attach new catheter injection cap.
−
−
−
−

Allow the pharmacologic agent to dwell undisturbed for 1 hour.
Withdraw 1 to 2 mL of 0.9% sodium chloride into a 10-mL syringe and label.
Withdraw 10 mL of 0.9% sodium chloride into the second 10-mL syringe and label.
Using aseptic technique, remove catheter injection cap and attach the 10-mL syringe containing 1 to 2 mL 0.9% sodium
chloride to external hub of the catheter.

− Attempt to aspirate. If blood return is noted, aspirate 5 mL of blood, discard, attach second syringe containing 10 mL of
0.9% sodium chloride and flush.
▪ In neonates: aspirate 0.5 mL, discard, and flush with 1 mL 0.9% sodium chloride
▪ In pediatric patients: aspirate 1 mL of blood, discard, and flush with 3 mL 0.9% sodium chloride
− If catheter lumen remains partially occluded, repeat above procedure. A second dose of the pharmacologic agent will
have to be ordered.
− Notify the medical team if catheter remains occluded after 2 attempts.
− Once catheter patency has been restored, clamp the catheter and aseptically attach new injection cap to the catheter.
Lastly, the catheter should be unclamped. If the catheter is not in use, heparinize catheter according to institutional
policies and procedures.
− Patients receiving alteplase should remain in the patient care setting for 2 to 4 hours; however, they do not have to be confined to bed. Instruct patient/caregiver to report any signs of allergic reaction, bleeding, fever, or shortness-of-breath.

Did You Know…
FDA Warning for Oral Sodium Phosphate Products for Bowel Cleansing
FDA has become aware of reports of acute phosphate nephropathy, a type of acute kidney injury, associated
with the use of oral sodium phosphate products (OSP) for bowel cleansing prior to colonoscopy or other procedures. These products include the prescription products, Visicol® and OsmoPrep®, and OSPs available overthe-counter without a prescription as laxatives (eg, Fleet® Phospho-soda). In some cases when used for bowel
cleansing, these serious adverse events have occurred in patients without identifiable factors that would put
them at risk for developing acute kidney injury. FDA cannot rule out, however, that some of these patients
were dehydrated prior to ingestion of OSPs or they did not drink sufficient fluids after ingesting OSP.
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Acute phosphate nephropathy is a form of acute kidney injury that is associated with deposits of calciumphosphate crystals in the renal tubules that may result in permanent renal function impairment. Acute phosphate nephropathy is a rare, serious adverse event that has been associated with the use of OSPs.
Patients who have an increased risk of acute phosphate nephropathy include the following: age greater 55;
hypovolemic or decreased intravascular volume; baseline kidney disease, bowel obstruction, or active colitis;
or concomitant medications that affect renal perfusion or function (such as diuretics, angiotensin converting
enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory
drugs [NSAIDs]).
As a result of new safety information received, FDA is requiring the manufacturer of Visicol® and OsmoPrep®, the two OSPs available by prescription only, to add a Boxed Warning to the labeling for these products.
FDA is also requiring that the manufacturer develop and implement a risk evaluation and mitigation strategy
(REMS), which will include a Medication Guide, to ensure that the benefits of these products outweigh the
risk of acute phosphate nephropathy, and to conduct a postmarketing clinical trial to further assess the risk of
acute kidney injury with use of these products.
FDA acknowledges that OSP products, in addition to use for bowel preparation, have a long history of safe use
as non-prescription products as laxatives (ie, for relief of constipation) and accordingly, they will continue to
be available over-the-counter for this use. However, in light of the risk of acute phosphate nephropathy, overthe-counter laxative OSP products should not be used for bowel cleansing. Consumers should only use OSPs
for bowel cleansing pursuant to a prescription from a healthcare professional. FDA intends to amend the labeling conditions for OSP products available in the OTC setting to address this concern with bowel cleansing use
and to improve the safe use of OSPs that are available over-the counter. FDA’s amendment to remove the professional labeling for bowel cleansing for these OSPs available over-the-counter will be published in a future
Federal Register notice.
FDA Warns Consumers About Tainted Weight Loss Pills
FDA is alerting consumers not to purchase or consume more than 25 different products marketed for weight
loss because they contain undeclared, active pharmaceutical ingredients that may put consumers’ health at risk.
An analysis found that the undeclared active pharmaceutical ingredients in some of these products include
sibutramine (a controlled substance), rimonabant (a drug not approved for marketing in the United States),
phenytoin (an anti-seizure medication), and phenolphthalein (a solution used in chemical experiments and a
suspected cancer-causing agent). Some of the amounts of active pharmaceutical ingredients far exceeded the
FDA-recommended levels, putting consumers' health at risk. These weight loss products (listed below), some
of which are marketed as “dietary supplements,” are promoted and sold on various Web sites and in some retail stores. Some of the products claim to be “natural” or to contain only “herbal” ingredients, but actually contain potentially harmful ingredients not listed on the product labels or in promotional advertisements. These
products have not been approved by the FDA.
Fatloss Slimming
Japan Lingzhi 24 Hours Diet
7 Day Herbal Slim
999 Fitness Essence
Imelda Perfect Slim
Perfect Slim
ProSlim Plus
Slim Express 360
Superslim
Venom Hyperdrive 3.0

2 Day Diet
5x Imelda Perfect Slimming
8 Factor Diet
Extrim Plus
Lida DaiDaihua
Perfect Slim 5x
Royal Slimming Formula
Slimtech
TripleSlim

3x Slimming Power
3 Day Diet
7 Diet Day/Night Formula
GMP
Miaozi Slim Capsules
Phyto Shape
Slim 3 in 1
Somotrim
Zhen de Shou
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FORMULARY UPDATE FOR OCTOBER 2008
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below. The formulary effective date was November
17, 2008, unless otherwise stated.
Added:
Temsirolimus (Torisel®)
Temsirolimus is a mammalian target of rapamycin (mTOR) inhibitor
used in the treatment of advanced
renal cell cancer. Data from clinical trials demonstrate that temsirolimus improves overall survival
and progression-free survival compared with interferon alone in patients with extensive metastatic disease and poor prognosis. Temsirolimus lengthens time to progression and is associated with promising results regarding response rates
with the 25-mg weekly dose. Temsirolimus and its active metabolite,
sirolimus, are metabolized by the
CYP 450 3A4 enzyme; therefore,
drug interactions with agents that
either induce or inhibit this enzyme
are possible. Live vaccines should
be avoided in patients receiving
temsirolimus because temsirolimus
produces a decreased immune response in patients and increases the
risk of infection. At this time, temsirolimus is recommended in patients with refractory disease or a
poor-risk prognosis.
25 mg/mL vials
SMOG Enema
A standardized SMOG enema formulation was added to the formulary. The formulation has a smaller
volume than other formulations and
contains equal parts. This formulation will be dispensed for any orders written for SMOG. The stan-

dardized formulation is composed of the following:
− sodium chloride 0.9%
(50 mL)
− magnesium sulfate 50%
(50 mL)
− mineral oil USP (50 mL)
− glycerin USP (50 mL)
Change in Restriction:
Intravenous Immune Globulin
(IVIG)
Orders for IVIG will require the
use of the pre-printed order form
for both inpatient and outpatient
orders. The order form requires
that the indication be documented. For inpatient orders,
IVIG must be reordered daily to
reduce potential waste. The restriction of attending physician
and service (ie, cardiothoracic
surgery, dermatology, immunology, infectious disease, general
pediatrics, hematology/
oncology, neurology, rheumatology, and transplant) will remain.
The form is awaiting approval
by the Forms Committee.
Line Extensions:
▪ Ipratropium (Atrovent® HFA)
17-microgram aerosol
solution
▪ Intravenous immune globulin
(Gammagard Liquid)
5-, 10-, 20-g vials
▪ Benzocaine/butamben/ tetracaine (ExactacaineTM)
2%-14%-2% spray
Deletions:
▪ Ipratropium (Atrovent®)
118-microgram aerosol
solution

▪ Intravenous immune globulin
(Gammagard S/D)
5-, 10-, 20-g vials
▪ Benzocaine, butamben, and tetracaine (Cetacaine®)
2%-14%-2% spray
Policy C61: Medication And
Intravenous Administration
The AdminRx addendum for policy
C61 was updated to change the
wording from “should scan” to
“must scan” patient armbands and
all medications prior to administration. Additionally, the medication
resolution process section of the
policy has been updated for units
using AdminRx. Nurses will do
chart checks every 12 hours at a
minimum. Discrepancies will be
reported through RxComm. The
pharmacist will be contacted via
phone or pager if omissions are
noted. The current 24-hour chart
checks and Pharmacy Discrepancy
Database will remain for units not
using AdminRx. Posting is still
pending on the Policy Web site.
Drug Information Service
Monday - Friday
9:00 AM - 5:30 PM
druginfo@musc.edu
792-3896
• Comprehensive information

concerning drug therapy
• Formulary management
• Patient-specific pharmaco-

therapy consultations
• Medication inservices
• Adverse drug reaction sur-

veillance and management
• Medication use evaluations
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FORMULARY UPDATE FOR NOVEMBER 2008
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below. The formulary effective date was December
15, 2008, unless otherwise stated.
Not Added:
Hyaluronidase (Hylenex®)
Hylenex® is indicated as an adjunct
to increase absorption and dispersion of other injected drugs and in
subcutaneous urography to improve
the resorption of radiopaque agents.
In addition, Hylenex® is also approved for hypodermolysis. Hylenex® is a purified preparation of
the human enzyme hyaluronidase
produced by genetically engineered
hamster cells. Hyaluronidase injection is currently available on our
formulary from bovine and ovine
sources (ie, Amphadase® and
Vitrase®) These products cost significantly less than Hylenex®. With
limited data in pediatric patients,
similar side effect profiles (even
with the recombinant formulation),
and a higher cost, it was decided
that Hylenex® would not be added
to the formulary.
Change in Restriction:
Bevacizumab (Avastin®)
Bevacizumab is indicated for use as
a chemotherapeutic agent in treat-

ing certain forms of cancer. It
was originally restricted to Hematology/Oncology physicians.
However, bevacizumab is also
useful in the treatment of neovascular (wet) age-related
macular degeneration (AMD)
and other ocular conditions.
Based on stability and sterility
studies, small doses of bevacizumab may be stored in the refrigerator for up to 3 weeks. The
FDA-approved product for neovascular AMD, ranibizumab
(Lucentis®), costs approximately
$2000 for one vial. Compounding single dose syringes of
bevacizumab would result in a
significant cost savings to the
institution and patients. Therefore, the restriction for bevacizumab was expanded to include
use as an ocular agent by Ophthalmology.
Line Extensions
▪ Meclizine 12.5-mg tablets
▪ Morphine 0.2-mg/mL
extemporaneous oral solution
▪ Oxytocin 30 units/500-mL
premix solution [NS]
▪ Propofol 10-mg/mL injection
(50-mL vial)

▪ Sodium chloride
(Hyper-Sal™) 7%
nebulization solution
▪ Triamcinolone acetonide
(Triesence®) 40-mg/mL
ophthalmic injection
Deletions:
▪ Oxytocin 30 units/500-mL
premix solution [D5LR]
▪ Triamcinolone acetonide
(Kenalog®) extemporaneous
ophthalmic injection
Anticoagulation Management
and Treatment Adult Policy and
Preprinted Order Forms
The organization is in the process
of developing an adult anticoagulation management program. Ultimately, preprinted order forms will
contain comprehensive guidelines
and treatment options for dosing of
warfarin, low molecular weight
heparin, fondaparinux, and unfractionated heparin, as well as orders
for anticoagulant reversal. These
protocols, forms, and guidelines
will be finalized and in place by
January 1, 2009 in accordance with
the Joint Commission National Patient Safety Goal 3E: Implementation of an Inpatient Anticoagulation
Program.

